Naprod Life Sciences has published an internal capacity overview for its MIDC Tarapur, Boisar manufacturing site. Company-reported annual capacity across the facility’s oncology injectable lines stands at approximately 3.5 million lyophilized units and 3 million liquid units (figures pending confirmation), alongside general (non-oncology) lyophilized capacity of roughly 10 million units and general liquid capacity of roughly 1 million units.
The site also runs solid-dose lines, with company-reported capacity of approximately 30 million tablets and 15 million capsules annually (figures pending confirmation). The update is intended to give prospective partners and regulatory reviewers a single reference point for the facility’s scale ahead of published, third-party-audited figures.